Valentis starts a Phase II study

VLTS and partner Roche (SWX:ROCZ) began U.S. Phase II testing in up to 40 patients of VLTS's IL-12 and interferon-alpha (IFN-a) gene medicine to treat squamous cell carcinoma of the head and neck. ...